Vaderis Therapeutics Ag
Clinical trials sponsored by Vaderis Therapeutics Ag, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a common fungal drug change how a new cancer drug acts? Results expected Oct 2026 (estimated)
- New drug aims to stop nosebleeds in rare genetic disorder Results expected Jan 2027 (estimated)
-
A pill to stop the bleeding? new hope for HHT nosebleeds
Disease control Not yet recruitingThis phase 3 trial tests whether an experimental oral drug called engasertib can reduce the number of nosebleeds in adults with moderate to severe hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and frequent bleeding. About 240 …
Phase 3 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a common fungal drug change how a new cancer drug acts?
Knowledge-focused Not yet recruitingResearchers are testing whether itraconazole, a known drug that blocks certain liver enzymes, changes how the body processes engasertib, an experimental drug. Healthy adults aged 18 to 55 will take engasertib alone and then with itraconazole. The study measures engasertib levels …
Phase 1 • Sponsor: Vaderis Therapeutics AG • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC